LEUKOCARE signs cooperation agreement with Sterigenics

LEUKOCARE AG, a privately-owned company developing innovative life science technologies, today announced the signing of a cooperation agreement with Sterigenics, a global leader for sterilization services.

As part of this cooperation, LEUKOCARE plans to use their Stabilizing and Protecting Solutions (SPS) technology together with Sterigenics’ irradiation expertise in order to establish new sterilization procedures for biotherapeutics, such as therapeutic antibodies. The project will aim to significantly improve the sterility and security for patients receiving biotherapeutics, as well as simplifying production processes and cost reductions.

“LEUKOCARE’s unique technologies make the company a significant and exciting enterprise with a vast potential for success,” commented Dirk Beelen , Vice President EMEAA Sales, Marketing and Business Development of Sterigenics. “We look forward to combining our expertise in irradiation with LEUKOCARE’s SPS technology in order to create new sterilization procedures for biologics, in particular, therapeutic antibodies.”

“We are delighted to start this project with Sterigenics, the international industry leaders for sterilization technology, as this will help us to establish a novel, state of the art method for processing biopharmaceuticals”, stated Michael Scholl, CEO of LEUKOCARE. “Sterigenics is the ideal partner to further develop the stabilization of biologics during sterilization using our SPS technology.”

At the same time as this collaboration, LEUKOCARE also announced the closing of a EUR 1.6 Million financing. LEUKOCARE’s existing group of private investors as well as the German state-owned bank KfW, which has been a shareholder in LEUKOCARE since 2006, participated in this capital increase. The investment strengthens LEUKOCARE’s financial position and paves the way for the next strategic steps in its development.